BLAZE-Limiting Approach in NMOSD

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 3, 2025

Conditions

Neuromyelitis Optica Spectrum Disorders (NMOSD)

Interventions

DRUG

Eculizumab administration

Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks

Trial Locations (1)

Huashan Hospital, Shanghai

All Listed Sponsors

lead

Huashan Hospital

OTHER

NCT06888622 - BLAZE-Limiting Approach in NMOSD | Biotech Hunter | Biotech Hunter